| Nov 14 |
Viridian Therapeutics Third Quarter 2024 Earnings: Revenues Beat Expectations, EPS Lags
|
| Nov 12 |
Viridian Therapeutics GAAP EPS of -$1.15 misses by $0.08, revenue of $0.09M beats by $0.04M
|
| Nov 12 |
Viridian Therapeutics Reports Third Quarter 2024 Financial Results and Recent Progress Including New FcRn Data
|
| Oct 31 |
Viridian Therapeutics Insiders Added US$616.3k Of Stock To Their Holdings
|
| Oct 23 |
Viridian Therapeutics' Superior Prospects Make It A Buy
|
| Sep 26 |
Forecasting The Future: 13 Analyst Projections For Viridian Therapeutics
|
| Sep 12 |
Viridian Therapeutics slides on pricing $225M securities offering
|
| Sep 12 |
Viridian Therapeutics Announces Pricing of Upsized Public Offering of Shares of Common Stock and Preferred Stock
|
| Sep 10 |
Viridian: Active TED Data Signifies Next Round Of Positive Data On The Way
|
| Sep 10 |
Viridian Therapeutics announces proposed underwritten offering
|
